BR112015027288A8 - uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit - Google Patents
uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit Download PDFInfo
- Publication number
- BR112015027288A8 BR112015027288A8 BR112015027288A BR112015027288A BR112015027288A8 BR 112015027288 A8 BR112015027288 A8 BR 112015027288A8 BR 112015027288 A BR112015027288 A BR 112015027288A BR 112015027288 A BR112015027288 A BR 112015027288A BR 112015027288 A8 BR112015027288 A8 BR 112015027288A8
- Authority
- BR
- Brazil
- Prior art keywords
- effects
- compositions
- kit
- composition
- therapeutic macromolecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
Abstract
abstract disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. the effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. the effects may also be enhanced with such compositions. tradução do resumo resumo patente de invenção: "nanocarreadores sintéticos tolerogênicos e macromoléculas terapêuticas para efeitos farmacodinâmicos acentuados ou reduzidos" a presente invenção refere-se a composições e métodos que fornecem efeitos farmacodinâmicos específicos para macromoléculas terapêuticas. os efeitos podem resultar de doses reduzidas de macromoléculas terapêuticas em combinação com doses de imunossupressor. os efeitos também podem ser acentuados com tais composições. 1/1
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361819517P | 2013-05-03 | 2013-05-03 | |
US61/819,517 | 2013-05-03 | ||
US201361881913P | 2013-09-24 | 2013-09-24 | |
US201361881851P | 2013-09-24 | 2013-09-24 | |
US201361881921P | 2013-09-24 | 2013-09-24 | |
US61/881,851 | 2013-09-24 | ||
US201361907177P | 2013-11-21 | 2013-11-21 | |
US61/907,177 | 2013-11-21 | ||
US201461948313P | 2014-03-05 | 2014-03-05 | |
US201461948384P | 2014-03-05 | 2014-03-05 | |
US61/948,313 | 2014-03-05 | ||
US61/948,384 | 2014-03-05 | ||
PCT/US2014/036687 WO2014179762A1 (en) | 2013-05-03 | 2014-05-02 | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015027288A2 BR112015027288A2 (pt) | 2017-07-25 |
BR112015027288A8 true BR112015027288A8 (pt) | 2019-12-24 |
BR112015027288B1 BR112015027288B1 (pt) | 2022-03-15 |
Family
ID=51841530
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015027280A BR112015027280A8 (pt) | 2013-05-03 | 2014-05-02 | nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
BR112015027281-9A BR112015027281B1 (pt) | 2013-05-03 | 2014-05-02 | Composições compreendendo macromoléculas terapêuticas e uma população de nanocarreadores sintéticos que são fixados a imunossupressores |
BR122020023215-3A BR122020023215B1 (pt) | 2013-05-03 | 2014-05-02 | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
BR112015027288-6A BR112015027288B1 (pt) | 2013-05-03 | 2014-05-02 | Composição que compreende um inibidor de mtor ligado a nanocarreadores sintéticos poliméricos |
BR112015027279A BR112015027279A8 (pt) | 2013-05-03 | 2014-05-02 | métodos e composições para acentuar células t reguladoras cd4+ |
BR112015027291A BR112015027291A8 (pt) | 2013-05-03 | 2014-05-02 | uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor |
BR112015027297-5A BR112015027297B1 (pt) | 2013-05-03 | 2014-05-02 | Uso de nanocarreadores sintéticos que são fixados a imunossupressores e de uma composição compreendendo os referidos nanocarreadores |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015027280A BR112015027280A8 (pt) | 2013-05-03 | 2014-05-02 | nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
BR112015027281-9A BR112015027281B1 (pt) | 2013-05-03 | 2014-05-02 | Composições compreendendo macromoléculas terapêuticas e uma população de nanocarreadores sintéticos que são fixados a imunossupressores |
BR122020023215-3A BR122020023215B1 (pt) | 2013-05-03 | 2014-05-02 | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015027279A BR112015027279A8 (pt) | 2013-05-03 | 2014-05-02 | métodos e composições para acentuar células t reguladoras cd4+ |
BR112015027291A BR112015027291A8 (pt) | 2013-05-03 | 2014-05-02 | uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor |
BR112015027297-5A BR112015027297B1 (pt) | 2013-05-03 | 2014-05-02 | Uso de nanocarreadores sintéticos que são fixados a imunossupressores e de uma composição compreendendo os referidos nanocarreadores |
Country Status (15)
Country | Link |
---|---|
US (13) | US20140335186A1 (pt) |
EP (7) | EP2991628A4 (pt) |
JP (17) | JP2016520051A (pt) |
KR (12) | KR20220025906A (pt) |
CN (16) | CN111053908A (pt) |
AU (15) | AU2014262166B2 (pt) |
BR (7) | BR112015027280A8 (pt) |
CA (5) | CA2910575C (pt) |
DK (1) | DK2991646T3 (pt) |
EA (6) | EA201592103A3 (pt) |
ES (1) | ES2842206T3 (pt) |
HU (1) | HUE052599T2 (pt) |
IL (14) | IL284924B2 (pt) |
MX (12) | MX2015015231A (pt) |
WO (5) | WO2014179773A2 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012149393A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
EA201592103A3 (ru) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для усиления cd4+ регуляторных t-клеток |
WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
WO2017025889A1 (en) * | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist |
WO2017083659A1 (en) * | 2015-11-12 | 2017-05-18 | New York University | Biodegradable polymeric nanoparticle conjugates and use thereof |
MX2018011012A (es) * | 2016-03-11 | 2019-03-28 | Selecta Biosciences Inc | Formulaciones y dosis de uricasa pegilada. |
JP7066632B2 (ja) * | 2016-05-09 | 2022-05-13 | アストラゼネカ・アクチエボラーグ | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
EP3494208A1 (en) * | 2016-08-05 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of gamma delta foxp3+ regulatory t cells and therapeutic uses thereof |
EP3494209A1 (en) * | 2016-08-05 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of mhcii restricted cd4+foxp3+ regulatory t cells and therapeutic uses thereof |
AU2018205496A1 (en) * | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
WO2018169811A1 (en) * | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
WO2019075360A1 (en) * | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
CN108295303A (zh) * | 2018-02-08 | 2018-07-20 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种钛金属植入物及其制备方法和用途 |
US20210023232A1 (en) * | 2018-03-29 | 2021-01-28 | Jenkem Technology Co., Ltd. (Tianjin) | Combination of polyethylene glycol and rapamycin and use thereof |
CN109045304B (zh) * | 2018-04-13 | 2022-04-05 | 中山大学 | 一种携带Polymerase I抑制剂的核仁靶向纳米载体及其制备方法和应用 |
US20220252574A1 (en) * | 2019-07-22 | 2022-08-11 | University Of Louisville Research Foundation, Inc. | Immunomodulatory compositions and methods of using |
US20220395563A1 (en) * | 2019-11-11 | 2022-12-15 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
KR20220146559A (ko) * | 2020-02-26 | 2022-11-01 | 셀렉타 바이오사이언시즈, 인크. | 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물 |
KR20230002613A (ko) * | 2020-04-14 | 2023-01-05 | 셀렉타 바이오사이언시즈, 인크. | 자가포식을 유도하기 위한 방법 및 조성물 |
CN113825832A (zh) * | 2020-07-28 | 2021-12-21 | 浙江大学 | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 |
WO2022022599A1 (zh) * | 2020-07-28 | 2022-02-03 | 浙江大学 | 一种体外诱导CD4 +Foxp3 +CD69 +Treg的扩增方法及其用途 |
CN112480244A (zh) * | 2020-11-24 | 2021-03-12 | 华科同济干细胞基因工程有限公司 | 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂 |
CN112961831B (zh) * | 2021-02-26 | 2022-10-11 | 仲恺农业工程学院 | 一种肠源外泌体的制备方法 |
WO2023086615A1 (en) * | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
Family Cites Families (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
ATE81467T1 (de) | 1987-02-24 | 1992-10-15 | Xoma Corp | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. |
US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
DE69518838T2 (de) | 1994-05-18 | 2001-05-03 | Protein Engineering Network Of | Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung |
US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
CA2200869A1 (en) | 1994-10-19 | 1996-05-02 | Bruce C. Trapnell | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
AU4176497A (en) | 1996-09-03 | 1998-03-26 | Health Research Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell fun ction |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
DE69739174D1 (de) | 1997-10-30 | 2009-01-29 | Leti Sl Lab | Tolerogenefragmente aus natürlichen allergenen |
US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
EP1042494A1 (en) | 1997-12-23 | 2000-10-11 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
WO1999034826A1 (en) | 1998-01-09 | 1999-07-15 | Circassia Limited | Methods and compositions for desensitisation |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
DE19951970A1 (de) | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
AU4724401A (en) | 2000-02-28 | 2001-09-12 | Genesegues Inc | Nanocapsule encapsulation system and method |
AU2001249182A1 (en) | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
US20060057553A1 (en) | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
AU2002338571A1 (en) | 2001-04-11 | 2002-11-11 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
ES2326040T3 (es) | 2001-10-19 | 2009-09-29 | Isotechnika Inc. | Sintesis de analogos de ciclosporina. |
GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
AU2003237416A1 (en) | 2002-06-04 | 2003-12-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Novel tolerogenic dendritic cells and therapeutic uses therefor |
SG167667A1 (en) | 2002-07-03 | 2011-01-28 | Coley Pharm Group Inc | Nucleic acid compositions for stimulating immune responses |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
ATE404196T1 (de) | 2002-11-29 | 2008-08-15 | Maria Grazia Roncarolo | Rapamycin und il-10 zur behandlung von autoimmunerkrankungen |
ZA200507562B (en) | 2003-03-26 | 2006-11-29 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
EP1694301A4 (en) | 2003-12-02 | 2009-11-18 | Cytimmune Sciences Inc | METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES |
KR101376715B1 (ko) | 2003-12-19 | 2014-03-27 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법 |
EP1850846A1 (en) | 2004-04-08 | 2007-11-07 | Laboratoires Serono SA | Composition comprising a jnk inhibitor and cyclosporin |
CA2571899A1 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
CA2583011A1 (en) * | 2004-10-05 | 2006-04-20 | Tanox, Inc. | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
BRPI0518101A (pt) | 2004-12-31 | 2008-10-28 | Iceutica Pty Ltd | métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso |
GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
CA2599758A1 (en) | 2005-03-08 | 2006-09-14 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising sirolimus and/or an analogue thereof |
KR20070121758A (ko) * | 2005-03-17 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 면역 억제 화합물의 주사가능한 조성물 |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
CA2603987A1 (en) | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
ATE541875T1 (de) | 2005-05-10 | 2012-02-15 | Univ Emory | Strategien zur freisetzung von wirkstoffen unter verwendung von mizellen und partikeln |
TW200711649A (en) | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
JPWO2007024026A1 (ja) | 2005-08-25 | 2009-03-05 | 明石 満 | T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子 |
CN1979166A (zh) * | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
AU2006320162B2 (en) | 2005-12-02 | 2013-07-25 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
MX2008007287A (es) | 2005-12-08 | 2008-10-27 | Univ Louisville Res Found | Metodos y composiciones para expandir celulas reguladoras t. |
WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
AU2007215328A1 (en) | 2006-02-13 | 2007-08-23 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
BRPI0709340A2 (pt) | 2006-03-27 | 2013-04-16 | Globeimmune Inc | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
AU2007243282A1 (en) | 2006-04-28 | 2007-11-08 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
MX2008015395A (es) * | 2006-08-18 | 2008-12-15 | Argos Therapeutics Inc | Uso de cd83 en terapias de combinacion. |
WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
CN101583379B (zh) | 2006-10-05 | 2013-04-03 | 约翰斯霍普金斯大学 | 使用优良聚合物纳米粒子的水溶性差药物的水可分散性口服,肠胃外和局部制剂 |
CN101646418B (zh) | 2006-10-12 | 2013-07-17 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
EP2077821B1 (en) | 2006-10-12 | 2019-08-14 | The University Of Queensland | Compositions and methods for modulating immune responses |
US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
US20100172994A1 (en) | 2006-11-22 | 2010-07-08 | University Of Florida Research Foundation, Inc. | Nanoparticles for Protection of Cells from Oxidative Stress |
WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
US9023984B2 (en) | 2006-12-29 | 2015-05-05 | The Regents Of The University Of Colorado, A Body Corporate | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
DK2481409T3 (en) | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
WO2008109852A2 (en) | 2007-03-07 | 2008-09-12 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
CA2683415C (en) | 2007-04-04 | 2020-12-08 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
JP2010523595A (ja) * | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | ポリ(アミノ酸)ターゲッティング部分 |
CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
JP2010523656A (ja) | 2007-04-12 | 2010-07-15 | エモリー・ユニバーシティ | ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 |
US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
KR20100035643A (ko) | 2007-06-05 | 2010-04-05 | 노파르티스 아게 | 성숙 수지상 세포에서의 허용유발 표현형의 유도 |
US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
EA018708B1 (ru) | 2007-07-09 | 2013-10-30 | Астразенека Аб | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US9340580B2 (en) | 2007-08-15 | 2016-05-17 | Circassia Limited | Peptide with multiple epitopes |
EP2200932A4 (en) * | 2007-09-21 | 2014-09-10 | Cytimmune Sciences Inc | NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
US20090142318A1 (en) * | 2007-11-30 | 2009-06-04 | Therakos, Inc. | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST |
AU2008346801A1 (en) | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | RNA interference for the treatment of heart failure |
US20110004148A1 (en) | 2008-02-08 | 2011-01-06 | Terumo Kabushiki Kaisha | Device for local intraluminal transport of a biologically and physiologically active agent |
EP2262489A2 (en) | 2008-02-28 | 2010-12-22 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Hollow nanoparticles and uses thereof |
EP2300022A2 (en) | 2008-04-25 | 2011-03-30 | Duke University | Regulatory b cells and their uses |
CA2724418A1 (en) | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
WO2009145238A1 (ja) | 2008-05-27 | 2009-12-03 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
US20120034157A1 (en) | 2010-08-03 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Artificial cells |
JP5705113B2 (ja) | 2008-08-15 | 2015-04-22 | サーカッシア リミテッド | Il−10産生の刺激のためのアレルゲン由来のt細胞抗原 |
US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
US9216188B2 (en) | 2008-09-04 | 2015-12-22 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
US20120015899A1 (en) | 2008-10-25 | 2012-01-19 | Plant Bioscience, Limited | Modified plant virus particles and uses therefor |
JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
AU2010206854A1 (en) | 2009-01-20 | 2011-08-04 | Myelin Repair Foundation, Inc. | Compositions and methods for induction of antigen-specific tolerance |
EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
JP5746053B2 (ja) | 2009-02-05 | 2015-07-08 | サーカッシア リミテッド | ワクチン用ペプチド |
KR20100099849A (ko) * | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
US20110223201A1 (en) | 2009-04-21 | 2011-09-15 | Selecta Biosciences, Inc. | Immunonanotherapeutics Providing a Th1-Biased Response |
WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
SG175142A1 (en) | 2009-04-27 | 2011-12-29 | Immuron Ltd | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
AU2010254550B2 (en) | 2009-05-27 | 2015-10-15 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents |
SG10201408480RA (en) | 2009-06-25 | 2015-02-27 | Crealta Pharmaceuticals Llc | Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy |
EP2470554B1 (en) | 2009-08-26 | 2017-06-28 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
CN101703781A (zh) | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
WO2011097511A1 (en) | 2010-02-05 | 2011-08-11 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | REGULATORY B CELLS (tBREGS) AND THEIR USE |
JP2013521002A (ja) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 誘導樹状細胞組成物及びその使用 |
US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
US8551487B2 (en) | 2010-05-07 | 2013-10-08 | Xoma Technology, Ltd. | Methods for the treatment of IL-1β related conditions |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
RU2016103126A (ru) | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
US20120058154A1 (en) | 2010-08-20 | 2012-03-08 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e |
JP2013538211A (ja) | 2010-08-23 | 2013-10-10 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗原に対する免疫反応を誘発する標的マルチエピトープ剤形 |
US9636309B2 (en) | 2010-09-09 | 2017-05-02 | Micell Technologies, Inc. | Macrolide dosage forms |
US10016371B2 (en) | 2010-10-22 | 2018-07-10 | University Of Florida Research Foundation | Antigen-specific, tolerance-inducing microparticles and uses thereof |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
JP2014507143A (ja) | 2011-02-08 | 2014-03-27 | ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム | アンチセンスオリゴヌクレオチド |
US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
CA2830948A1 (en) | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012149393A2 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells |
JP6174572B2 (ja) | 2011-05-16 | 2017-08-02 | ジェンザイム・コーポレーション | メトトレキサートを用いる免疫寛容の誘導 |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
US20130058902A1 (en) | 2011-09-06 | 2013-03-07 | Selecta Biosciences, Inc. | Dendritic cell subsets for generating induced tolerogenic dendritic cells and related compositions and methods |
US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013058812A1 (en) * | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
JP6348064B2 (ja) | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
AU2013221212B2 (en) | 2012-02-17 | 2018-08-09 | The Children's Hospital Of Philadelphia | AAV vector compositions and methods for gene transfer to cells, organs and tissues |
CA2871786C (en) | 2012-04-24 | 2021-11-16 | Ohio State Innovation Foundation | Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
EP2968499A4 (en) | 2013-03-15 | 2016-11-30 | Haplomics Inc | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE IN FACTOR VIII REPLACEMENT THERAPIES IN PATIENTS WITH HEMOPHILIA A |
CN105431170B (zh) | 2013-04-08 | 2019-10-29 | 爱荷华大学研究基金会 | 嵌合腺相关病毒/博卡病毒细小病毒载体 |
WO2014179771A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
EA201592103A3 (ru) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для усиления cd4+ регуляторных t-клеток |
AU2014274894A1 (en) | 2013-06-04 | 2015-11-26 | Selecta Biosciences, Inc. | Repeated administration of non-immunosupressive antigen specific immunotherapeutics |
US9388222B2 (en) | 2013-10-06 | 2016-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified Pseudomonas exotoxin A |
US9276815B2 (en) * | 2013-12-27 | 2016-03-01 | Dell Products L.P. | N-node virtual link trunking (VLT) systems management plane |
EP2916319A1 (en) | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
KR102390075B1 (ko) | 2014-03-09 | 2022-04-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 오르니틴 트랜스카르바밀라아제(otc) 결핍증의 치료에 유용한 조성물 |
GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
US20150358333A1 (en) * | 2014-06-04 | 2015-12-10 | Grandios Technologies, Llc | Geo-location and biometric presence security |
US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
US20150374815A1 (en) | 2014-06-25 | 2015-12-31 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
MX2017005904A (es) | 2014-11-05 | 2017-06-27 | Selecta Biosciences Inc | Metodos y composiciones relacionadas con nanoportadores sinteticos con rapamicina en un estado estable, super-saturado. |
WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
EP3413917A4 (en) | 2016-02-10 | 2019-09-11 | Pfizer Inc | THERAPEUTIC NANOPARTICLES COMPRISING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME |
MX2018011012A (es) | 2016-03-11 | 2019-03-28 | Selecta Biosciences Inc | Formulaciones y dosis de uricasa pegilada. |
WO2018039465A1 (en) | 2016-08-25 | 2018-03-01 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
US11104887B2 (en) | 2017-01-03 | 2021-08-31 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
AU2018205496A1 (en) | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
AU2019226051A1 (en) | 2018-02-26 | 2020-09-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Drug delivery systems |
EP3823980A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of otc constructs and vectors |
WO2020018587A1 (en) | 2018-07-16 | 2020-01-23 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
JP2022535121A (ja) | 2019-06-04 | 2022-08-04 | セレクタ バイオサイエンシーズ インコーポレーテッド | ペグ化ウリカーゼの処方物および用量 |
EP4048269A1 (en) | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
EP4054531A1 (en) | 2019-11-08 | 2022-09-14 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
-
2014
- 2014-05-02 EA EA201592103A patent/EA201592103A3/ru unknown
- 2014-05-02 AU AU2014262166A patent/AU2014262166B2/en active Active
- 2014-05-02 EP EP14791089.7A patent/EP2991628A4/en active Pending
- 2014-05-02 BR BR112015027280A patent/BR112015027280A8/pt not_active Application Discontinuation
- 2014-05-02 WO PCT/US2014/036700 patent/WO2014179773A2/en active Application Filing
- 2014-05-02 BR BR112015027281-9A patent/BR112015027281B1/pt active IP Right Grant
- 2014-05-02 CN CN201911307714.6A patent/CN111053908A/zh active Pending
- 2014-05-02 MX MX2015015231A patent/MX2015015231A/es unknown
- 2014-05-02 CA CA2910575A patent/CA2910575C/en active Active
- 2014-05-02 CN CN202010594054.0A patent/CN111686255A/zh active Pending
- 2014-05-02 DK DK14791496.4T patent/DK2991646T3/da active
- 2014-05-02 KR KR1020227004756A patent/KR20220025906A/ko not_active Application Discontinuation
- 2014-05-02 IL IL284924A patent/IL284924B2/en unknown
- 2014-05-02 BR BR122020023215-3A patent/BR122020023215B1/pt active IP Right Grant
- 2014-05-02 JP JP2016512090A patent/JP2016520051A/ja active Pending
- 2014-05-02 KR KR1020157034133A patent/KR20160003217A/ko not_active IP Right Cessation
- 2014-05-02 EA EA201592107A patent/EA201592107A1/ru unknown
- 2014-05-02 CA CA2910578A patent/CA2910578C/en active Active
- 2014-05-02 KR KR1020157034143A patent/KR20160003219A/ko not_active IP Right Cessation
- 2014-05-02 KR KR1020227004763A patent/KR20220025911A/ko not_active IP Right Cessation
- 2014-05-02 JP JP2016512086A patent/JP2016517889A/ja active Pending
- 2014-05-02 CN CN201910552107.XA patent/CN110251676A/zh active Pending
- 2014-05-02 JP JP2016512091A patent/JP7028556B2/ja active Active
- 2014-05-02 CN CN202010594335.6A patent/CN111760025A/zh active Pending
- 2014-05-02 WO PCT/US2014/036687 patent/WO2014179762A1/en active Application Filing
- 2014-05-02 WO PCT/US2014/036699 patent/WO2014179772A2/en active Application Filing
- 2014-05-02 AU AU2014262165A patent/AU2014262165B2/en active Active
- 2014-05-02 CN CN201480032251.6A patent/CN105283175A/zh active Pending
- 2014-05-02 EP EP14791147.3A patent/EP2991685A4/en active Pending
- 2014-05-02 JP JP2016512093A patent/JP6818549B2/ja active Active
- 2014-05-02 CN CN201910552053.7A patent/CN110251675A/zh active Pending
- 2014-05-02 WO PCT/US2014/036697 patent/WO2014179770A1/en active Application Filing
- 2014-05-02 KR KR1020227004758A patent/KR20220025907A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201480037076.XA patent/CN105338979A/zh active Pending
- 2014-05-02 MX MX2015015229A patent/MX2015015229A/es unknown
- 2014-05-02 US US14/269,042 patent/US20140335186A1/en active Pending
- 2014-05-02 US US14/269,056 patent/US10357483B2/en active Active
- 2014-05-02 KR KR1020227004761A patent/KR20220025910A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201480037123.0A patent/CN105339012A/zh active Pending
- 2014-05-02 EP EP14792080.5A patent/EP2991631A4/en active Pending
- 2014-05-02 CN CN201910874452.5A patent/CN110639024A/zh active Pending
- 2014-05-02 EA EA201592105A patent/EA201592105A1/ru unknown
- 2014-05-02 AU AU2014262163A patent/AU2014262163A1/en not_active Abandoned
- 2014-05-02 EA EA201592106A patent/EA201592106A3/ru unknown
- 2014-05-02 CA CA2910584A patent/CA2910584A1/en active Pending
- 2014-05-02 MX MX2015015221A patent/MX2015015221A/es unknown
- 2014-05-02 CN CN201911069542.3A patent/CN110841067A/zh active Pending
- 2014-05-02 BR BR112015027288-6A patent/BR112015027288B1/pt active IP Right Grant
- 2014-05-02 US US14/269,048 patent/US10668053B2/en active Active
- 2014-05-02 KR KR1020227004760A patent/KR20220025909A/ko not_active Application Discontinuation
- 2014-05-02 CN CN201910874364.5A patent/CN110694077A/zh active Pending
- 2014-05-02 EP EP14791119.2A patent/EP2991629A4/en active Pending
- 2014-05-02 EA EA201592102A patent/EA201592102A1/ru unknown
- 2014-05-02 EP EP14791567.2A patent/EP2991630A4/en active Pending
- 2014-05-02 KR KR1020157034104A patent/KR20160003830A/ko not_active IP Right Cessation
- 2014-05-02 US US14/269,058 patent/US10335395B2/en active Active
- 2014-05-02 CN CN201911069459.6A patent/CN110841066A/zh active Pending
- 2014-05-02 MX MX2015015225A patent/MX2015015225A/es unknown
- 2014-05-02 EA EA201592104A patent/EA201592104A3/ru unknown
- 2014-05-02 WO PCT/US2014/036696 patent/WO2014179769A2/en active Application Filing
- 2014-05-02 KR KR1020157034102A patent/KR20160003212A/ko not_active IP Right Cessation
- 2014-05-02 BR BR112015027279A patent/BR112015027279A8/pt not_active Application Discontinuation
- 2014-05-02 KR KR1020157034121A patent/KR20160003215A/ko not_active IP Right Cessation
- 2014-05-02 IL IL292190A patent/IL292190A/en unknown
- 2014-05-02 ES ES14791496T patent/ES2842206T3/es active Active
- 2014-05-02 US US14/269,047 patent/US10434088B2/en active Active
- 2014-05-02 JP JP2016512094A patent/JP6580558B2/ja active Active
- 2014-05-02 CN CN201911306104.4A patent/CN111068061A/zh active Pending
- 2014-05-02 MX MX2015015223A patent/MX2015015223A/es unknown
- 2014-05-02 KR KR1020227004759A patent/KR20220025908A/ko not_active IP Right Cessation
- 2014-05-02 CN CN201480031937.3A patent/CN105307641A/zh active Pending
- 2014-05-02 CA CA2910417A patent/CA2910417C/en active Active
- 2014-05-02 EP EP20167362.1A patent/EP3763359A1/en active Pending
- 2014-05-02 AU AU2014262155A patent/AU2014262155A1/en not_active Abandoned
- 2014-05-02 HU HUE14791496A patent/HUE052599T2/hu unknown
- 2014-05-02 BR BR112015027291A patent/BR112015027291A8/pt not_active Application Discontinuation
- 2014-05-02 AU AU2014262162A patent/AU2014262162B2/en active Active
- 2014-05-02 KR KR1020157034120A patent/KR20160003214A/ko not_active IP Right Cessation
- 2014-05-02 JP JP2016512092A patent/JP6760838B2/ja active Active
- 2014-05-02 CN CN201480034670.3A patent/CN105338968A/zh active Pending
- 2014-05-02 IL IL284732A patent/IL284732B2/en unknown
- 2014-05-02 CA CA2910583A patent/CA2910583C/en active Active
- 2014-05-02 MX MX2015015230A patent/MX2015015230A/es unknown
- 2014-05-02 EP EP14791496.4A patent/EP2991646B1/en active Active
- 2014-05-02 MX MX2021005697A patent/MX2021005697A/es unknown
- 2014-05-02 CN CN201480032224.9A patent/CN105263478A/zh active Pending
- 2014-05-02 BR BR112015027297-5A patent/BR112015027297B1/pt active IP Right Grant
- 2014-05-02 US US14/269,054 patent/US10357482B2/en active Active
-
2015
- 2015-10-22 IL IL24221615A patent/IL242216B/en active IP Right Grant
- 2015-10-26 IL IL242273A patent/IL242273B/en active IP Right Grant
- 2015-10-26 IL IL242271A patent/IL242271B/en active IP Right Grant
- 2015-10-26 IL IL242272A patent/IL242272B/en active IP Right Grant
- 2015-10-26 IL IL24227015A patent/IL242270B/en active IP Right Grant
- 2015-10-30 MX MX2021001982A patent/MX2021001982A/es unknown
- 2015-10-30 MX MX2021001878A patent/MX2021001878A/es unknown
- 2015-10-30 MX MX2022009538A patent/MX2022009538A/es unknown
- 2015-10-30 MX MX2021001879A patent/MX2021001879A/es unknown
- 2015-10-30 MX MX2021012348A patent/MX2021012348A/es unknown
-
2018
- 2018-12-10 JP JP2018231206A patent/JP6983144B2/ja active Active
-
2019
- 2019-01-15 JP JP2019004287A patent/JP7134885B2/ja active Active
- 2019-05-13 US US16/410,876 patent/US20200069659A1/en not_active Abandoned
- 2019-06-06 US US16/433,622 patent/US20200069660A1/en active Pending
- 2019-06-11 US US16/438,147 patent/US11298342B2/en active Active
- 2019-08-26 US US16/550,725 patent/US20200113874A1/en active Pending
- 2019-08-28 JP JP2019155456A patent/JP2020015741A/ja active Pending
- 2019-10-15 AU AU2019250117A patent/AU2019250117B2/en active Active
- 2019-10-24 IL IL270135A patent/IL270135B/en unknown
- 2019-10-24 IL IL270133A patent/IL270133B/en unknown
- 2019-10-28 JP JP2019195263A patent/JP7427419B2/ja active Active
- 2019-12-02 JP JP2019217946A patent/JP2020073488A/ja active Pending
-
2020
- 2020-01-04 AU AU2020200065A patent/AU2020200065B2/en active Active
- 2020-01-24 AU AU2020200565A patent/AU2020200565A1/en not_active Abandoned
- 2020-02-05 AU AU2020200824A patent/AU2020200824A1/en not_active Abandoned
- 2020-04-24 US US16/858,349 patent/US20200360350A1/en active Pending
- 2020-05-21 IL IL274852A patent/IL274852B/en unknown
- 2020-05-21 AU AU2020203308A patent/AU2020203308A1/en not_active Abandoned
- 2020-07-21 IL IL276205A patent/IL276205B/en active IP Right Grant
-
2021
- 2021-01-04 JP JP2021000191A patent/JP2021073198A/ja active Pending
- 2021-03-24 US US17/211,459 patent/US20220071968A1/en not_active Abandoned
- 2021-04-04 IL IL282045A patent/IL282045B/en unknown
- 2021-09-30 JP JP2021162235A patent/JP2022025069A/ja active Pending
- 2021-11-29 JP JP2021193530A patent/JP2022043071A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200157A patent/AU2022200157A1/en active Pending
- 2022-03-09 US US17/690,437 patent/US20230032226A1/en active Pending
- 2022-03-09 AU AU2022201641A patent/AU2022201641A1/en active Pending
- 2022-03-15 IL IL291394A patent/IL291394A/en unknown
- 2022-05-06 JP JP2022076787A patent/JP7440833B2/ja active Active
- 2022-05-06 JP JP2022076702A patent/JP2022122871A/ja active Pending
- 2022-05-11 AU AU2022203142A patent/AU2022203142A1/en active Pending
- 2022-05-25 AU AU2022203540A patent/AU2022203540A1/en active Pending
- 2022-12-09 JP JP2022197386A patent/JP2023039981A/ja active Pending
-
2023
- 2023-05-11 AU AU2023202955A patent/AU2023202955A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015027288A8 (pt) | uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
BR112016020618A8 (pt) | oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido | |
BR112015020389A2 (pt) | compostos carbazol úteis como inibidores de bromodomínio | |
BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
BR112015015898A8 (pt) | composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
BR112015030595A2 (pt) | moduladores de receptor de estrogênio de azetidina e usos dos mesmos | |
CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
BR112015015870A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
BR112015026238A8 (pt) | composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit | |
BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
BR112018002427A8 (pt) | Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
BR112018014661A2 (pt) | composição e composição para uso | |
TN2015000403A1 (en) | Methods for treating psoriasis using an anti-il-23 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/05/2014, OBSERVADAS AS CONDICOES LEGAIS. |